Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06481592 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 10 to 12v11
  2. Eligibility criteria expanded, about 80 wordsv10 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 9 to 10v9
  4. Study sites: 7 to 9v8
  5. Study sites: 4 to 7v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 3 to 4v6
  2. Start date changed from estimate of Oct 2024 to Oct 29, 2024v5
  3. Study sites: 2 to 3v4
  4. Study sites: 1 to 2v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Trial Details
NCT Number NCT06481592
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Endometrial Cancer
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov